Belluscura (BELL) Competitors GBX 0.75 0.00 (0.00%) As of 10/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock BELL vs. AVO, RUA, SUN, POLX, MHC, DEMG, SN, NIOX, MXCT, and EKFShould you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Polarean Imaging (POLX), MyHealthChecked (MHC), Deltex Medical Group (DEMG), Smith & Nephew (SN), NIOX Group (NIOX), MaxCyte (MXCT), and EKF Diagnostics (EKF). These companies are all part of the "medical devices" industry. Belluscura vs. Its Competitors Advanced Oncotherapy RUA Life Sciences Surgical Innovations Group Polarean Imaging MyHealthChecked Deltex Medical Group Smith & Nephew NIOX Group MaxCyte EKF Diagnostics Belluscura (LON:BELL) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation. Do insiders and institutionals have more ownership in BELL or AVO? 0.7% of Belluscura shares are held by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are held by institutional investors. 7.1% of Belluscura shares are held by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is BELL or AVO more profitable? Advanced Oncotherapy has a net margin of 0.00% compared to Belluscura's net margin of -1,030.73%. Advanced Oncotherapy's return on equity of -67.34% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets Belluscura-1,030.73% -102.62% -43.53% Advanced Oncotherapy N/A -67.34%-11.73% Which has higher earnings & valuation, BELL or AVO? Belluscura has higher revenue and earnings than Advanced Oncotherapy. Belluscura is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelluscura£1.80M1.67-£29.55M-£13.10-0.06Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A Which has more risk & volatility, BELL or AVO? Belluscura has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Does the media favor BELL or AVO? In the previous week, Belluscura's average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score. Company Overall Sentiment Belluscura Neutral Advanced Oncotherapy Neutral SummaryAdvanced Oncotherapy beats Belluscura on 6 of the 10 factors compared between the two stocks. Get Belluscura News Delivered to You Automatically Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BELL vs. The Competition Export to ExcelMetricBelluscuraMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£3.01M£2.57B£6.19B£2.57BDividend YieldN/A2.44%5.70%5.37%P/E Ratio-0.06190.3185.624,237.12Price / Sales1.67131.80615.4999,406.89Price / Cash8.0015.9937.1027.90Price / Book0.063.8312.238.11Net Income-£29.55M£132.05M£3.33B£5.89B7 Day PerformanceN/A2.79%1.17%-0.62%1 Month PerformanceN/A3.85%6.85%0.73%1 Year Performance-93.32%17.68%58.93%128.71% Belluscura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BELLBelluscuraN/AGBX 0.75flatN/AN/A£3.01M£1.80M-0.0624AVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 11-4.3%N/A-21.3%£7.14M£4.11M-2.6148Gap DownSUNSurgical Innovations GroupN/AGBX 0.60+4.2%N/A+2.7%£5.36M£11.92M-383.9780Gap UpPOLXPolarean ImagingN/AGBX 0.47+10.1%N/A-70.0%£5.13M£2.56M-468.0028Gap DownMHCMyHealthCheckedN/AGBX 9.07-9.3%N/A-52.9%£4.72M£3.22M-241.1216Gap DownDEMGDeltex Medical GroupN/AN/AN/AN/A£187K£1.76M-0.1537Gap UpHigh Trading VolumeSNSmith & Nephew3.1857 of 5 starsGBX 1,324.50-2.4%GBX 1,379.33+4.1%+20.2%£14.52B£7.08B47.6918,452High Trading VolumeNIOXNIOX GroupN/AGBX 74.60+0.8%GBX 90+20.6%+9.4%£309.22M£46M5,968.0092MXCTMaxCyteN/AGBX 1.62-4.7%N/A-99.4%£170.11M£35.75M-4.0580Positive NewsHigh Trading VolumeEKFEKF DiagnosticsN/AGBX 28.80-5.6%N/A-5.6%£136.97M£50.22M2,133.33356Gap Down Related Companies and Tools Related Companies AVO Competitors RUA Competitors SUN Competitors POLX Competitors MHC Competitors DEMG Competitors SN Competitors NIOX Competitors MXCT Competitors EKF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BELL) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belluscura plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belluscura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BELL Stock Alerts